JP2018528206A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528206A5 JP2018528206A5 JP2018510877A JP2018510877A JP2018528206A5 JP 2018528206 A5 JP2018528206 A5 JP 2018528206A5 JP 2018510877 A JP2018510877 A JP 2018510877A JP 2018510877 A JP2018510877 A JP 2018510877A JP 2018528206 A5 JP2018528206 A5 JP 2018528206A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- inhibitor
- cancer
- pharmaceutically acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 85
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 33
- 201000011510 cancer Diseases 0.000 claims description 31
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- -1 RDEA436 Chemical compound 0.000 claims description 13
- 230000035772 mutation Effects 0.000 claims description 12
- 229940124647 MEK inhibitor Drugs 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 10
- 239000003112 inhibitor Substances 0.000 claims description 9
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 9
- 239000012664 BCL-2-inhibitor Substances 0.000 claims description 8
- 229940123711 Bcl2 inhibitor Drugs 0.000 claims description 8
- 101000605639 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 claims description 8
- 102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 claims description 8
- 229940121647 egfr inhibitor Drugs 0.000 claims description 8
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 8
- 229960004066 trametinib Drugs 0.000 claims description 8
- 206010009944 Colon cancer Diseases 0.000 claims description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims description 7
- CLRSLRWKONPSRQ-CPOWQTMSSA-N (1s)-1-(4-chlorophenyl)-6-methoxy-2-[4-[methyl-[[4-(4-methyl-3-oxopiperazin-1-yl)cyclohexyl]methyl]amino]phenyl]-7-propan-2-yloxy-1,4-dihydroisoquinolin-3-one Chemical compound C1([C@@H]2N(C(=O)CC=3C=C(C(=CC=32)OC(C)C)OC)C=2C=CC(=CC=2)N(C)CC2CCC(CC2)N2CC(=O)N(C)CC2)=CC=C(Cl)C=C1 CLRSLRWKONPSRQ-CPOWQTMSSA-N 0.000 claims description 6
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 6
- 239000012828 PI3K inhibitor Substances 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 claims description 5
- 229950004847 navitoclax Drugs 0.000 claims description 5
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 4
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 claims description 4
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 4
- 206010069755 K-ras gene mutation Diseases 0.000 claims description 4
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 4
- 229960002465 dabrafenib Drugs 0.000 claims description 4
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001433 erlotinib Drugs 0.000 claims description 4
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 230000002018 overexpression Effects 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims description 3
- FIMYFEGKMOCQKT-UHFFFAOYSA-N 3,4-difluoro-2-(2-fluoro-4-iodoanilino)-n-(2-hydroxyethoxy)-5-[(3-oxooxazinan-2-yl)methyl]benzamide Chemical compound FC=1C(F)=C(NC=2C(=CC(I)=CC=2)F)C(C(=O)NOCCO)=CC=1CN1OCCCC1=O FIMYFEGKMOCQKT-UHFFFAOYSA-N 0.000 claims description 3
- 210000003679 cervix uteri Anatomy 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- MWUFVYLAWAXDHQ-HMNLTAHHSA-N (2e,5s,6s,8z,10r,11s)-17-(ethylamino)-5,6,15-trihydroxy-10,11-dimethyl-12-oxabicyclo[12.4.0]octadeca-1(18),2,8,14,16-pentaene-7,13-dione Chemical compound O([C@@H](C)[C@H](C)\C=C/C(=O)[C@@H](O)[C@@H](O)C/C=C/1)C(=O)C=2C\1=CC(NCC)=CC=2O MWUFVYLAWAXDHQ-HMNLTAHHSA-N 0.000 claims description 2
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical group N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N ABT-737 Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 206010052358 Colorectal cancer metastatic Diseases 0.000 claims description 2
- 208000012609 Cowden disease Diseases 0.000 claims description 2
- 201000002847 Cowden syndrome Diseases 0.000 claims description 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000008770 Multiple Hamartoma Syndrome Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- VIUAUNHCRHHYNE-JTQLQIEISA-N N-[(2S)-2,3-dihydroxypropyl]-3-(2-fluoro-4-iodoanilino)-4-pyridinecarboxamide Chemical compound OC[C@@H](O)CNC(=O)C1=CC=NC=C1NC1=CC=C(I)C=C1F VIUAUNHCRHHYNE-JTQLQIEISA-N 0.000 claims description 2
- 208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 102000001708 Protein Isoforms Human genes 0.000 claims description 2
- 108010029485 Protein Isoforms Proteins 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 2
- 208000009621 actinic keratosis Diseases 0.000 claims description 2
- 210000004100 adrenal gland Anatomy 0.000 claims description 2
- 229960001686 afatinib Drugs 0.000 claims description 2
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 claims description 2
- 210000003445 biliary tract Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000000621 bronchi Anatomy 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 229960005395 cetuximab Drugs 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 210000004696 endometrium Anatomy 0.000 claims description 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 229960002584 gefitinib Drugs 0.000 claims description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 210000003494 hepatocyte Anatomy 0.000 claims description 2
- QQLKULDARVNMAL-UHFFFAOYSA-N icotinib Chemical compound C#CC1=CC=CC(NC=2C3=CC=4OCCOCCOCCOC=4C=C3N=CN=2)=C1 QQLKULDARVNMAL-UHFFFAOYSA-N 0.000 claims description 2
- 229950007440 icotinib Drugs 0.000 claims description 2
- 210000003228 intrahepatic bile duct Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000000244 kidney pelvis Anatomy 0.000 claims description 2
- 229960004891 lapatinib Drugs 0.000 claims description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 229950008001 matuzumab Drugs 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 210000000214 mouth Anatomy 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims description 2
- 229950008835 neratinib Drugs 0.000 claims description 2
- JWNPDZNEKVCWMY-VQHVLOKHSA-N neratinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 JWNPDZNEKVCWMY-VQHVLOKHSA-N 0.000 claims description 2
- 229950010203 nimotuzumab Drugs 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 229960001972 panitumumab Drugs 0.000 claims description 2
- 229960002087 pertuzumab Drugs 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 210000000813 small intestine Anatomy 0.000 claims description 2
- 201000010700 sporadic breast cancer Diseases 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003862 vemurafenib Drugs 0.000 claims description 2
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims description 2
- 229960001183 venetoclax Drugs 0.000 claims description 2
- AGBSXNCBIWWLHD-FQEVSTJZSA-N siremadlin Chemical compound COC1=NC(OC)=NC=C1C(N1C(C)C)=NC2=C1[C@H](C=1C=CC(Cl)=CC=1)N(C=1C(N(C)C=C(Cl)C=1)=O)C2=O AGBSXNCBIWWLHD-FQEVSTJZSA-N 0.000 claims 3
- 229940000425 combination drug Drugs 0.000 claims 2
- UIYYKSUHRZUEQP-VIFPVBQESA-N 5-fluoro-2-(2-fluoro-4-methylsulfanylanilino)-n-[(2s)-2-hydroxypropoxy]-1-methyl-6-oxopyridine-3-carboxamide Chemical compound FC1=CC(SC)=CC=C1NC1=C(C(=O)NOC[C@H](C)O)C=C(F)C(=O)N1C UIYYKSUHRZUEQP-VIFPVBQESA-N 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029862 Barrett adenocarcinoma Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical group O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- RDSACQWTXKSHJT-NSHDSACASA-N n-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2s)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide Chemical compound C1CC1(C[C@H](O)CO)S(=O)(=O)NC=1C(OC)=CC(F)=C(F)C=1NC1=CC=C(I)C=C1F RDSACQWTXKSHJT-NSHDSACASA-N 0.000 claims 1
- 208000037244 polycythemia vera Diseases 0.000 claims 1
- HKSQZEGSMBFHGC-UHFFFAOYSA-N pyrimidine-4-carboxamide Chemical compound NC(=O)C1=CC=NC=N1 HKSQZEGSMBFHGC-UHFFFAOYSA-N 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 15
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- 229940083338 MDM2 inhibitor Drugs 0.000 description 3
- 239000012819 MDM2-Inhibitor Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- KNTZCGBYFGEMFR-UHFFFAOYSA-N (propan-2-ylazaniumyl)formate Chemical compound CC(C)NC(O)=O KNTZCGBYFGEMFR-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 description 1
- 241000511343 Chondrostoma nasus Species 0.000 description 1
- 241001645982 Crax Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562211080P | 2015-08-28 | 2015-08-28 | |
| US62/211,080 | 2015-08-28 | ||
| US201562243337P | 2015-10-19 | 2015-10-19 | |
| US62/243,337 | 2015-10-19 | ||
| US201562250574P | 2015-11-04 | 2015-11-04 | |
| US62/250,574 | 2015-11-04 | ||
| PCT/IB2016/055050 WO2017037579A1 (en) | 2015-08-28 | 2016-08-24 | Mdm2 inhibitors and combinations thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020190870A Division JP2021042222A (ja) | 2015-08-28 | 2020-11-17 | Ｍｄｍ２阻害剤およびその組み合わせ物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528206A JP2018528206A (ja) | 2018-09-27 |
| JP2018528206A5 true JP2018528206A5 (cg-RX-API-DMAC7.html) | 2019-10-03 |
Family
ID=56877086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510877A Pending JP2018528206A (ja) | 2015-08-28 | 2016-08-24 | Ｍｄｍ２阻害剤およびその組み合わせ物 |
| JP2020190870A Pending JP2021042222A (ja) | 2015-08-28 | 2020-11-17 | Ｍｄｍ２阻害剤およびその組み合わせ物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020190870A Pending JP2021042222A (ja) | 2015-08-28 | 2020-11-17 | Ｍｄｍ２阻害剤およびその組み合わせ物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20190060309A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4241850A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018528206A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180041677A (cg-RX-API-DMAC7.html) |
| CN (2) | CN111821306A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016314082B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2992221C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2962460T3 (cg-RX-API-DMAC7.html) |
| IL (2) | IL257015B (cg-RX-API-DMAC7.html) |
| RU (2) | RU2020142739A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017037579A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201613576A (en) | 2014-06-26 | 2016-04-16 | Novartis Ag | Intermittent dosing of MDM2 inhibitor |
| WO2018075823A1 (en) | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US11285154B2 (en) | 2017-03-29 | 2022-03-29 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
| AU2018242612B2 (en) * | 2017-03-31 | 2020-05-21 | Novartis Ag | Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors |
| WO2019040511A1 (en) * | 2017-08-22 | 2019-02-28 | University Of Maryland Batimore | DOUBLE INHIBITORS OF BCL-2 AND HDM2 FAMILIES BY CO-MIMETTISM OF ALPHA BH3 AND P53 PROPELLERS |
| JP2020536855A (ja) * | 2017-09-26 | 2020-12-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | がんを治療するための組成物及び方法 |
| EP3694518A1 (en) * | 2017-10-12 | 2020-08-19 | Novartis AG | Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers |
| WO2019133992A1 (en) * | 2017-12-31 | 2019-07-04 | Evergreen Biosciences | Compositions for cryopreservation and methods of use thereof |
| WO2019174576A1 (zh) * | 2018-03-12 | 2019-09-19 | 罗欣药业(上海)有限公司 | 咪唑并吡咯酮化合物及其应用 |
| TWI791794B (zh) * | 2018-03-20 | 2023-02-11 | 瑞士商諾華公司 | 藥物組合 |
| CN110772521A (zh) | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| JP7058345B2 (ja) * | 2018-07-31 | 2022-04-21 | アセンテージ ファーマ（スーチョウ）カンパニー，リミティド | Ｂｃｌ－２阻害剤及びＭＤＭ２阻害剤の組合せ製品並びに疾患の予防及び／又治療におけるその使用 |
| MX2020009759A (es) | 2018-07-31 | 2020-10-08 | Ascentage Pharma Suzhou Co Ltd | Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop. |
| WO2020024834A1 (en) | 2018-07-31 | 2020-02-06 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases |
| KR20210106484A (ko) | 2018-12-20 | 2021-08-30 | 노파르티스 아게 | Hdm2-p53 상호작용 억제제와 bcl2 억제제의 조합 및 암 치료를 위한 이의 용도 |
| WO2021018032A1 (en) * | 2019-07-26 | 2021-02-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Pharmaceutical composition of mdm2 inhibitor and use thereof for preventing and/or treating disease |
| US12343352B2 (en) | 2019-12-03 | 2025-07-01 | Ascentage Pharma (Suzhou) Co., Ltd. | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors |
| TW202200147A (zh) * | 2020-05-26 | 2022-01-01 | 韓商韓美藥品股份有限公司 | Ｂｅｌｖａｒａｆｅｎｉｂ用於癌症治療 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| JP2024157057A (ja) * | 2021-06-29 | 2024-11-07 | 国立大学法人 東京大学 | バレット食道の治療用組成物 |
| CN117562907B (zh) * | 2023-11-17 | 2025-08-22 | 广州医科大学 | 一种提升抗癌效果的可口服吉非替尼复合物及其制备方法与应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU2503A (sh) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| TWI350285B (en) | 2002-03-13 | 2011-10-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| RS50569B (sr) | 2004-06-11 | 2010-05-07 | Japan Tobacco Inc. | Derivati 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2h-pirido (2,3-d)pirimidina i slična jedinjenja za lečenje raka |
| EP2361905B1 (en) | 2005-05-18 | 2013-03-06 | Array Biopharma Inc. | Heterocyclic Inhibitors of MEK and methods of use thereof |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| EP2370566A1 (en) * | 2008-12-03 | 2011-10-05 | Università Degli Studi Di Torino | Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| US8440693B2 (en) * | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US8859535B2 (en) * | 2011-06-20 | 2014-10-14 | Novartis Ag | Hydroxy substituted isoquinolinone derivatives |
| US20140348819A1 (en) * | 2011-06-24 | 2014-11-27 | Dana-Farber Cancer Institute, Inc. | Methods of Treating Cancer |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| EP2752191A1 (en) * | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| DK3068393T5 (da) * | 2013-11-11 | 2022-08-22 | Amgen Inc | Kombinationsterapi som inkluderer en mdm2-inhibitor og et eller flere yderligere farmaceutisk aktive midler til behandlingen af kræftformer |
| WO2015084804A1 (en) * | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
| WO2015095834A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using erk1/2 and bcl-2 family inhibitors |
| KR20160100975A (ko) | 2013-12-23 | 2016-08-24 | 노파르티스 아게 | 제약 조합물 |
-
2016
- 2016-08-24 AU AU2016314082A patent/AU2016314082B2/en not_active Ceased
- 2016-08-24 JP JP2018510877A patent/JP2018528206A/ja active Pending
- 2016-08-24 KR KR1020187005360A patent/KR20180041677A/ko not_active Ceased
- 2016-08-24 US US15/756,094 patent/US20190060309A1/en not_active Abandoned
- 2016-08-24 WO PCT/IB2016/055050 patent/WO2017037579A1/en not_active Ceased
- 2016-08-24 CA CA2992221A patent/CA2992221C/en active Active
- 2016-08-24 EP EP23177095.9A patent/EP4241850A3/en not_active Withdrawn
- 2016-08-24 ES ES16760803T patent/ES2962460T3/es active Active
- 2016-08-24 RU RU2020142739A patent/RU2020142739A/ru unknown
- 2016-08-24 CN CN202010783071.9A patent/CN111821306A/zh not_active Withdrawn
- 2016-08-24 RU RU2018110770A patent/RU2740091C2/ru active
- 2016-08-24 CN CN201680062336.8A patent/CN108348520A/zh active Pending
- 2016-08-24 EP EP16760803.3A patent/EP3340989B1/en not_active Revoked
-
2018
- 2018-01-18 IL IL257015A patent/IL257015B/en unknown
-
2019
- 2019-07-09 AU AU2019204938A patent/AU2019204938B2/en not_active Ceased
-
2020
- 2020-09-09 IL IL277239A patent/IL277239B/en unknown
- 2020-11-17 JP JP2020190870A patent/JP2021042222A/ja active Pending
-
2021
- 2021-03-01 US US17/188,726 patent/US20210260059A1/en not_active Abandoned
-
2023
- 2023-01-13 US US18/154,717 patent/US20230398115A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528206A5 (cg-RX-API-DMAC7.html) | ||
| RU2018110770A (ru) | Ингибиторы mdm2 и их комбинации | |
| CN102089007B (zh) | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| US20240299388A1 (en) | Erk1/2 and shp2 inhibitors combination therapy | |
| AU2014233805B2 (en) | Combination therapy comprising a B-Raf inhibitor and a second inhibitor | |
| JP2015524472A5 (cg-RX-API-DMAC7.html) | ||
| RU2018120330A (ru) | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения | |
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| AU2012335663B2 (en) | Method of treating a proliferative disease | |
| JP2007502820A5 (cg-RX-API-DMAC7.html) | ||
| JP2014505735A5 (cg-RX-API-DMAC7.html) | ||
| JP2014525454A5 (cg-RX-API-DMAC7.html) | ||
| JP2012515787A5 (cg-RX-API-DMAC7.html) | ||
| JP2019525948A5 (cg-RX-API-DMAC7.html) | ||
| JP2011530607A5 (cg-RX-API-DMAC7.html) | ||
| RU2014112198A (ru) | Синергические композиции ингибиторов pi3k и мек | |
| RU2015108755A (ru) | Комбинация ингибитора pik3 и ингибитора с-мет | |
| JP2015529194A5 (cg-RX-API-DMAC7.html) | ||
| CA2914310A1 (en) | Pharmaceutical combinations | |
| Zhong et al. | Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways | |
| CN102958518A (zh) | 磷脂酰肌醇3-激酶抑制剂和抗糖尿病化合物的组合 | |
| Heppt et al. | Combination therapy of melanoma using kinase inhibitors | |
| JP2018516982A5 (ja) | 免疫療法用組み合わせ組成物 | |
| CN119792535A (zh) | 抗肿瘤组合物 |